Intentar ORO - Gratis
Reality of Universal Cancer Prevention & Cure
BioSpectrum Asia
|BioSpectrum Asia Dec 2021
Oncology is the largest pharmaceutical therapeutic area, and big pharma is investing billions of dollars in search of the elusive cancer cure. With all this investment and innovation, will we ever see a universal cancer cure? Let’s find out.
-
Oncology treatment has come a long way since the advent of chemotherapy in the 1940s. There have been tremendous advancements in the field of oncology, especially over the last two decades, resulting in improved quality of life and survival rates. There are more than 1,300 medicines and vaccines in development to tackle cancer, as of January 2021 (source: PhRMA). Many innovative therapies have been launched and pharmaceutical companies continue to invest significantly in oncology research to advance the cancer treatment market.
“Cancer has undergone huge changes in the last five years as new treatments that harness the immune system to restore the balance between cancer cells and healthy cells have been extensively evaluated. Drugs like PD-1/L1 inhibitors have revolutionised the treatment of late-stage melanoma, lung cancer and renal cancer, dramatically improving five-year survival rates,” said Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence, UK.
“We also now have genetically modified cell therapies that produce impressive response rates for advanced forms of blood cancer. More generally, cancer populations are being defined not just by the tumor location but by an ever-growing list of biomarkers that have relevance for prognosis and the selection of appropriate targeted therapies. Chemotherapy is still an essential part of cancer treatment, but is increasingly being displaced or supplemented by innovative new cancer drugs,” added Chancellor.
The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. Let’s look at the next wave of innovations making headlines in the cancer space:
Next wave of innovations
Esta historia es de la edición BioSpectrum Asia Dec 2021 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Reshaping Asia's Healthcare with mRNA Innovation
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Momentum in Motion: What Will Shape APAC's Life Sciences Landscape in 2026?
Asia-Pacific's life sciences sector is growing rapidly, driven by its scale, diversity and resilience. Accelerating demographic change and strong investment in innovation position the region to outpace global growth and shape the future of healthcare.
5 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
The Future of mRNA Is Being Built in APAC
Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent. While political dynamics in the United States have slowed momentum, experts emphasise that the science underpinning mRNA technology remains sound. To fully realise its potential, the region will need greater coordination across borders, including regulatory harmonisation and joint development pathways, to build a resilient mRNA ecosystem capable of addressing shared health challenges and driving long-term innovation.
25 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
How Precision Medicine Is Reshaping Cancer Care
Despite major advances in cancer detection and treatment, high recurrence rates and progression to advanced disease continue to challenge outcomes across Asia-making precision medicine a critical catalyst for shifting cancer care from disease management toward treat-to-cure. By leveraging molecular insights, biomarker testing and collaborative healthcare ecosystems, precision medicine offers the potential to deliver more effective, personalised and sustainable cancer care for patients across the region.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Repligen introduces next-generation chromatography resins
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India
Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh
\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.
1 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cartherics names Dr lan Nisbet as CEO
Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Neurophet ropes in Josh Cohen as Head of Americas Business
South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.
1 min
BioSpectrum Asia Jan 2026
Translate
Change font size

